Mechanism of O-GlcNAcylation regulating liver lipid synthesis in mice through FASN
- PMID: 39950311
- DOI: 10.1096/fj.202402451RR
Mechanism of O-GlcNAcylation regulating liver lipid synthesis in mice through FASN
Abstract
Nonalcoholic fatty liver disease (NAFLD) has become one of the most common chronic liver diseases. O-Linked attachment of beta-N-acetylglucosamine (O-GlcNAc) are ubiquitous post-translational modifications of proteins as "nutrient sensors" and "stress receptors" in the body that are involved in maintaining normal cellular physiological functions. Increased levels of O-GlcNAcylation have been found in the liver samples of patients with NAFLD and nonalcoholic steatohepatitis. However, the role of O-GlcNAcylation in the development and pathogenesis of NAFLD remains unclear. Here, we sought to determine the specific role of O-GlcNAcylation in NAFLD. In this study, the results demonstrated that inhibition of O-GlcNAc transferase (OGT) led to decreased expression of liver lipid synthesis genes and proteins in vitro. In addition, we showed that fatty acid synthase (FASN) expression was positively correlated with O-GlcNAcylation levels. Immunoprecipitation and pulldown assays confirmed the interaction between FASN and OGT at the serine 1483 of FASN, to inhibit K48-linked ubiquitination and degradation of FASN, thereby promoting hepatic lipid accumulation and the development of NAFLD. Administration of the OGT inhibitor OSMI-1 to ob/ob mice led to decreased liver lipid accumulation, further confirming our in vitro experimental results. Finally, we used liver-specific Ogt gene knockout mice fed a high-fat diet to elucidate the specific mechanism of O-GlcNAcylation on NAFLD and found that knockdown of the Ogt gene led to decreased liver lipid accumulation. In conclusion, our findings show that inhibiting the O-GlcNAcylation of FASN at the S1483 site promotes the K48-linked ubiquitination and degradation of FASN and leads to inhibition of lipid accumulation in the liver. Treatment with the OGT inhibitor OSMI-1 leads to decreased lipid accumulation in the liver, suggesting that targeting O-GlcNAcylation sites could be a potential therapeutic strategy for alleviating NAFLD.
Keywords: O‐GlcNAcylation; fatty acid synthase; liver lipid synthesis; mice; ubiquitination.
© 2025 Federation of American Societies for Experimental Biology.
Similar articles
-
Dual regulation of fatty acid synthase (FASN) expression by O-GlcNAc transferase (OGT) and mTOR pathway in proliferating liver cancer cells.Cell Mol Life Sci. 2021 Jul;78(13):5397-5413. doi: 10.1007/s00018-021-03857-z. Epub 2021 May 27. Cell Mol Life Sci. 2021. PMID: 34046694 Free PMC article.
-
Hepatocyte-specific O-GlcNAc transferase downregulation ameliorates nonalcoholic steatohepatitis by improving mitochondrial function.Mol Metab. 2023 Sep;75:101776. doi: 10.1016/j.molmet.2023.101776. Epub 2023 Jul 13. Mol Metab. 2023. PMID: 37453647 Free PMC article.
-
O-GlcNAcylation regulates long-chain fatty acid metabolism by inhibiting ACOX1 ubiquitination-dependent degradation.Int J Biol Macromol. 2024 May;266(Pt 2):131151. doi: 10.1016/j.ijbiomac.2024.131151. Epub 2024 Mar 26. Int J Biol Macromol. 2024. PMID: 38547945
-
Biological Functions and Potential Therapeutic Significance of O-GlcNAcylation in Hepatic Cellular Stress and Liver Diseases.Cells. 2024 May 9;13(10):805. doi: 10.3390/cells13100805. Cells. 2024. PMID: 38786029 Free PMC article. Review.
-
Emerging Role of Protein O-GlcNAcylation in Liver Metabolism: Implications for Diabetes and NAFLD.Int J Mol Sci. 2023 Jan 21;24(3):2142. doi: 10.3390/ijms24032142. Int J Mol Sci. 2023. PMID: 36768465 Free PMC article. Review.
References
REFERENCES
-
- Sayuti NH, Muhammad Nawawi KN, Goon JA, Mokhtar NM, Makpol S, Tan JK. A review of the effects of fucoxanthin on NAFLD. Nutrients. 2023;15(8):1954.
-
- Gonzalez‐rellan MJ, Parracho T, Heras V, et al. Hepatocyte‐specific O‐GlcNAc transferase downregulation ameliorates nonalcoholic steatohepatitis by improving mitochondrial function. Mol Metab. 2023;75:101776.
-
- Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options. JHEP Rep. 2019;1(4):312‐328.
-
- Harrison SA, Gawrieh S, Roberts K, et al. Prospective evaluation of the prevalence of non‐alcoholic fatty liver disease and steatohepatitis in a large middle‐aged US cohort. J Hepatol. 2021;75(2):284‐291.
-
- Gorg B, Karababa A, Schutz E, et al. O‐GlcNAcylation‐dependent upregulation of HO1 triggers ammonia‐induced oxidative stress and senescence in hepatic encephalopathy. J Hepatol. 2019;71(5):930‐941.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous